EGFR and non-small cell lung carcinoma: A retrospective analysis of NSCLC patients with EGFR mutation and brain involvement published in 2017 demonstrated a survival advantage for the addition of cerebral irradiation to first-/second-generation EGFR inhibitors [59]: In this study, the rate of brain progression was slightly lower for patients treated with TKI and stereotactic (SRT) or whole-brain radiotherapy (WBRT) than for those treated with TKI alone, producing a significant benefit in terms of OS.